CLINICAL_TRIALS ClinicalTrials.gov record update

Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03175224
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:39.207158+00:00
Published At: 2025-06-27T00:00:00+00:00
Record Updated At: 2025-06-27
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Solid Tumors", "Advanced Cancer", "Renal Cancer", "Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma", "NSCLC", "Lung Cancer", "Brain Tumor", "Glioblastoma Multiforme", "EGFR Gene Mutation", "MET Amplification", "HGF", "Thyroid Cancer", "Pancreatic Cancer", "Colon Cancer", "MET Alteration", "MET Fusion", "Exon 14 Skipping"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-06-27"
protocolSection.identificationModule.nctId: "NCT03175224"
protocolSection.identificationModule.officialTitle: "Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.